Abstract
Psoriasis (Ps), psoriatic arthritis (PsA), and SAPHO syndrome are diseases of unknown etiology that share common clinical features; however, family studies support the hypothesis of a genetic background for each of these diseases. To study the two common single-nucleotide polymorphisms (SNP) in the murine-double-minute-2-(Mdm2) and p53 genes in patients with Ps, PsA, and SAPHO syndrome. Genomic DNA was obtained from 187 patients with Ps, 50 with PsA, and 36 with SAPHO as well as 478 healthy controls. Mdm2-gene SNP T309G and p53-gene SNP G72C genotypes were determined by the polymerase chain reaction. Genotype and allele frequencies were analyzed with χ2-tests. Among the patients with Ps and PsA, no differences in allele or genotype frequencies of the p53-gene SNP G72C and Mdm2-gene SNP T309G were detected. However, in the SAPHO patients group, the frequencies of the Mdm2 SNP309 G allele and the genotype SNP 309 GG were significantly increased compared with the controls (G allele: 51.4 vs. 38.7%, P = 0.034; genotype GG: 36.1 vs. 14.2%, P = 0.002). In addition, the frequencies of the p53 SNP72 C allele and the genotype SNP 72 CC were also increased in the SAPHO patients cohort (C allele: 36.1 vs. 25.6%, P = 0.05; genotype CC: 16.7 vs. 6.3%, P = 0.05). SAPHO syndrome may be linked to an imbalance between MDM2 and p53 regulation with a “weak” p53-response associated with the Mdm2 SNP 309 G allele. In contrast, the p53 network does not seem to play a major role in pathogenesis of Ps or PsA.
References
Hannuksela-Svahn A, Pääkkö P, Autio P et al (1999) Expression of p53 protein before and after PUVA treatment in psoriasis. Acta Derm Venereol 79:195–199
Salvador G, Sanmarti R, Garcia-Peiró A et al (2005) p53 expression in rheumatoid and psoriatic arthritis synovial tissue and association with joint damage. Ann Rheum Dis 64:183–187
Chamot AM, Benhamou CL, Kahn MF et al (1987) Acne-pustulosis-hyperostosis-osteitis syndrome. Results of a national survey: 85 cases. Rev Rhum Mal Osteoartic 54:187–196
Schilling F, Kessler S (2000) SAPHO syndrome: clinico-rheumatologic and radiologic differentiation and classification of a patient sample of 86 cases. Z Rheumatol 59:1–28
Vogelstein B, Lane D, Levine AJ (2000) Surfing the p53 network. Nature 408:307–310
Gudkov AV, Komarova EA (2007) Dangerous habits of a security guard: the two faces of p53 as a drug target. Hum Mol Genet 16:67–72
Bond GL, Hu W, Bond EE, Robins H et al (2004) A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumour suppressor pathway and accelerates tumour formation in humans. Cell 119:591–602
Dumont P, Leu JI, Della Pietra AC 3rd et al (2003) The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33:357–365
Wright V, Moll JMH (1976) In: Seronegative Polyarthritis. North Holland Publishing Company, Amsterdam
Assmann G, Wieczorek S, Wibisono D et al (2008) The p53 G72C and MDM2 T309G single nucleotide polymorphisms in patients with Wegener`s granulomatosis. Clin Exp Rheumatol 26:72–75
Butt C, Peddle L, Greenwood C et al (2006) Association of functional variants of PTPN22 and tp53 in psoriatic arthritis: a case–control study. Arthritis Res Ther 8:R27
Gladman DD, Rahman P, Krueger GG et al (2008) Clinical and genetic registries in psoriatic disease. J Rheumatol 35:1458–1463
Rahman P, Elder JT (2005) Genetic epidemiology of psoriasis and psoriatic arthritis. Ann Rheum Dis 64:ii37–ii39
Dumolard A, Gaudin P, Juvin R et al (1999) SAPHO syndrome or psoriatic arthritis? A familial case study. Rheumatology (Oxford) 38:463–467
Queiro R, Moreno P, Sarasqueta C et al (2008) Synovitis-acne-pustulosis-hyperostosis-osteitis syndrome and psoriatic arthritis exhibit a different immunogenetic profile. Clin Exp Rheumatol 26:125–128
Momand J, Wu HH, Dasgupta G (2000) MDM2-master regulator of the p53 tumor suppressor protein. Gene 242:15–29
Wawrzynow B, Zylicz A, Wallace M, Hupp T, Zylicz M (2007) MDM2 chaperones the p53 tumor suppressor. J Biol Chemistry 282:32603–32612
Acknowledgments
We wish to thank A. Menzel (Luxemburg) for SNP genotyping. This study was supported by HOMFOR grants to GA and KR. GA, KR, TW, MP conceived and designed the study. GA, MM, ADW, CP contributed to the acquisition of the samples or study data by patients interview or chart reviews. GA and KR developed the statistical study design for this study and performed the statistical analysis. All authors were involved in the interpretation of the data. All authors read and approved the final manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Assmann, G., Wagner, A.D., Monika, M. et al. Single-nucleotide polymorphisms p53 G72C and Mdm2 T309G in patients with psoriasis, psoriatic arthritis, and SAPHO syndrome. Rheumatol Int 30, 1273–1276 (2010). https://doi.org/10.1007/s00296-009-1136-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-009-1136-8